Abpro Holdings Inc.
ABPO Healthcare Biotechnology
Abpro Holdings Inc.’s revenue for fiscal 2024 (year ended December 2024) was $183,000.00, up 50.0% from fiscal 2023. In the quarter to June 2026, EPS grew 89.3% and free cash flow was flat, each against the same quarter a year earlier.
Follow ABPO
Abpro Holdings Inc. (ABPO) P/E ratio
As of 16 October 2026, Abpro Holdings Inc. (ABPO) trades at a P/E ratio of 0.2×. Over the past ten years it has ranged from 0.0× (March 2026) to 87.6× (March 2023); the current reading is higher than 75% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2024 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEXI NexImmune, Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| CARM Carisma Therapeutics Inc. compare | n/m |
| MLEC Moolec Science SA compare | n/m |
| ITRMF Iterum Therapeutics PLC compare | n/m |
| ABPO Abpro Holdings Inc. | 0.2× |
| PTIX Atrinsic Inc. compare | 0.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)